International Journal of Radiation Research

en Impact of spiral tomotherapy combined with intensity-modulated radiotherapy for nasopharyngeal carcinoma Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;">Background: Nasopharyngeal carcinoma (NPC) is a radiosensitive tumor located in a complex anatomical region, necessitating highly conformal radiotherapy. Spiral tomotherapy (TOMO), an advanced form of intensity-modulated radiotherapy (IMRT), integrates dose-guided and image-guided delivery to improve tumor targeting. This study aimed to compare the clinical efficacy, toxicity, and dosimetric advantages of spiral TOMO versus conventional IMRT in NPC patients. Materials and Methods: A total of 80 NPC patients treated between September 2017 and February 2019 were retrospectively reviewed. Patients were assigned to either spiral TOMO (n = 40) or IMRT (n = 40) groups. Radiotherapy doses ranged from 50.7 to 71.1 Gy, delivered over 6–6.5 weeks. Clinical response was assessed using RECIST criteria, while treatment toxicity was graded according to the standards of the American Society for Radiation Oncology. Dosimetric evaluation included target coverage and organ-at-risk (OAR) sparing parameters. Results: Spiral TOMO achieved a total short-term efficacy rate of 97.5%, compared to 95.0% for IMRT. Although myelosuppression rates were comparable (P>0.05), the TOMO group showed significantly lower rates of acute skin reactions (12.5% vs. 60%) and acute dry mouth (10% vs. 45%) (P<0.05). Dosimetric analysis confirmed improved dose conformity and reduced exposure to OARs such as the parotid glands and spinal cord in the TOMO group. Conclusion: Spiral TOMO demonstrated superior short-term efficacy and lower toxicity compared to IMRT in the treatment of NPC. Its advantages in dose distribution and organ preservation support its clinical use as an effective radiotherapy technique for nasopharyngeal carcinoma.</div> Nasopharyngeal carcinoma, spiral tomotherapy, IMRT, radiotherapy efficacy, Toxicity reduction. 245 250 http://ijrr.com/browse.php?a_code=A-10-1-1482&slc_lang=en&sid=1 Y. Zhou meizipo0725592032@163.com 7900319475328460032993 7900319475328460032993 Yes Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China G. Wang 7900319475328460032994 7900319475328460032994 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China Z. He 7900319475328460032995 7900319475328460032995 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China Y. Zhang 7900319475328460032996 7900319475328460032996 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China Y. Zhou 7900319475328460032997 7900319475328460032997 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China H. Li 7900319475328460032998 7900319475328460032998 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China Q. Jing 7900319475328460032999 7900319475328460032999 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China J. Qian 7900319475328460033000 7900319475328460033000 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China Q. Sun 7900319475328460033001 7900319475328460033001 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China X. Zhang 7900319475328460033002 7900319475328460033002 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China H. Jiang 7900319475328460033003 7900319475328460033003 No Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233099, China